Nivolumab a New Standard of Care in Adjuvant Settings in Esophageal and Gastroesophageal Junctional Cancer Patients-Reference-Cited by-同舟云学术

Nivolumab a New Standard of Care in Adjuvant Settings in Esophageal and Gastroesophageal Junctional Cancer Patients

Published:2021-10 Issue:05 Volume:42 Page:468-469
ISSN:0971-5851
Container-title:Indian Journal of Medical and Paediatric Oncology
language:en
Short-container-title:Indian J Med Paediatr Oncol

Author:

Rajappa Senthil J.¹,Nusrath Syed²

Affiliation:

1. Department of Medical Oncology, Basavatarakam Indo American Cancer Institute and Research Institute, Hyderabad, Telangana, India

2. Department of Surgical Oncology, Division of Upper Gastrointestinal Surgery, Basavatarakam Indo American Cancer Institute and Research Institute, Hyderabad, Telangana, India

Publisher

Georg Thieme Verlag KG

Subject

Oncology,Pediatrics, Perinatology and Child Health

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0041-1739189.pdf

Reference11 articles.

1. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience;M Blum Murphy;Cancer,2017

2. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer;R J Kelly;N Engl J Med,2021

3. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Y-K Kang;Lancet,2017

4. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial;K Kato;Lancet Oncol,2019

5. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers;F Petrelli;Eur J Cancer,2017